Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HemaSure

This article was originally published in The Gray Sheet

Executive Summary

Private placement of 3.7 mil. shares nets $26 mil. to fund a two-year capacity expansion project for the firm's r/LS red blood cell filtration system. The expansion is anticipated to result in a greater-than-ten-fold increase in production capability in order to meet demand for leukoreduced blood products. The project will commence in the second quarter and further the American Red Cross goal of 100% leukoreduction by the end of 2000

You may also be interested in...



California Federal Court Rejects Settlement Proposal In Coppertone ‘Mineral-Based’ Sunscreen Case

Beiersdorf and former owner Bayer are on the verge of settling a proposed class action in California’s Northern District challenging “mineral-based” claims on Coppertone sunscreens that also contain chemical UV filters. However, the parties will have to try again with their proposed terms.

QUOTED. 11 May 2021. Phil Brown.

The MHRA is in listening mode as it gathers feedback to shape the UKCA marking for medical devices. See what Phil Brown, regulatory director of the Association of British HealthTech Industries, said about it here.

Changing Standards Of Care Trip Up Companies At US FDA Advisory Committees

Following a memorable cancer drug advisory panel meeting where FDA explained how accelerated approvals may be more at risk due to changing standard of care, ChemoCentryx’s ANCA-vasculitis treatment runs into trouble because of another drug’s changing indication during their Phase III study.

UsernamePublicRestriction

Register

MT013084

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel